BCAB vs BCDA

BioAtla, Inc. vs BioCardia, Inc. — Valuation Comparison 2026

BCAB

Biotechnology
BioAtla, Inc.
Quality
3.4
out of 10
Value Trap
30
LOW
Price
$4.05
Last close
Models
7/13
Active
VS

BCDA

Biotechnology
BioCardia, Inc.
Quality
4.4
out of 10
Value Trap
40
WARN
Price
$0.92
Last close
Models
9/13
Active

Model-by-Model Comparison

ModelType BCAB Fair ValueBCAB Upside BCDA Fair ValueBCDA Upside
Bayesian DCF Intrinsic $1.80 -55.7% $0.27 -70.6%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $22.05 +444.4% $1.52 +66.0%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for BCAB vs BCDA — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

BCAB vs BCDA — Which Stock Is More Undervalued?

BCDA scores higher with a 4.4/10 quality rating vs BCAB's 3.4/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing BioAtla, Inc. (BCAB) and BioCardia, Inc. (BCDA) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

BCAB currently trades at $4.05 with a QOC of 3.4/10, while BCDA trades at $0.92 with a QOC of 4.4/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).